X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20) 20
index medicus (19) 19
female (15) 15
oncology (13) 13
male (12) 12
middle aged (9) 9
pharmacology & pharmacy (9) 9
adult (8) 8
aged (8) 8
medicine & public health (8) 8
japan (7) 7
studies (6) 6
tumors (6) 6
adolescent (5) 5
diabetes (5) 5
pharmacology/toxicology (5) 5
sunitinib (5) 5
treatment outcome (5) 5
cancer (4) 4
clinical trials (4) 4
drug therapy (4) 4
efficacy (4) 4
insulin (4) 4
internal medicine (4) 4
japan - epidemiology (4) 4
medical colleges (4) 4
microbial sensitivity tests (4) 4
original (4) 4
pancreas (4) 4
patients (4) 4
pharmacology (4) 4
research (4) 4
retrospective studies (4) 4
analysis (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
asian continental ancestry group (3) 3
birth weight (3) 3
carboplatin (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
cell lung-cancer (3) 3
chemotherapy (3) 3
child (3) 3
crizotinib (3) 3
diabetes mellitus (3) 3
drug administration schedule (3) 3
glucose (3) 3
hematology, oncology and palliative medicine (3) 3
infectious diseases (3) 3
original article (3) 3
pediatrics (3) 3
phase i studies (3) 3
renal-cell carcinoma (3) 3
safety (3) 3
tyrosine kinase inhibitor (3) 3
young adult (3) 3
administration, oral (2) 2
age (2) 2
amplification (2) 2
anti-bacterial agents - adverse effects (2) 2
anti-bacterial agents - pharmacokinetics (2) 2
anti-bacterial agents - pharmacology (2) 2
antibacterial agents (2) 2
antifungal agents - therapeutic use (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - pharmacokinetics (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
automobile industry (2) 2
azithromycin - adverse effects (2) 2
base sequence (2) 2
beta (2) 2
biology and life sciences (2) 2
biomarkers, tumor - blood (2) 2
biotechnology & applied microbiology (2) 2
blood glucose - metabolism (2) 2
blood sugar (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
cardiovascular disease (2) 2
cells (2) 2
children (2) 2
chromosomes, human, pair 21 (2) 2
complications and side effects (2) 2
diabetes mellitus, type 1 - epidemiology (2) 2
diabetes-mellitus (2) 2
diabetic endocrinology (2) 2
dna (2) 2
dosage and administration (2) 2
dose-response relationship, drug (2) 2
down syndrome - genetics (2) 2
drug resistance, bacterial (2) 2
endocrine system diseases (2) 2
endocrinology (2) 2
endocrinology & metabolism (2) 2
everolimus (2) 2
fluorescence (2) 2
for-gestational-age (2) 2
fulminant type 1 diabetes mellitus (2) 2
gefitinib (2) 2
genetics & heredity (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Investigational new drugs, ISSN 0167-6997, 03/2019, Volume 37, Issue 3, pp. 591 - 591
In the original publication of this article, the license subtype should be CC BY and not CC BY-NC. 
Pancreas | Neuroendocrine tumors | Metastases
Journal Article
Investigational New Drugs, ISSN 0167-6997, 12/2012, Volume 30, Issue 6, pp. 2352 - 2363
Background Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine... 
Phase I | Medicine & Public Health | Tyrosine kinase inhibitor | Oncology | Dacomitinib | PF-00299804 | Japanese patients | Pharmacology/Toxicology | Epidermal growth factor receptor | GEFITINIB | ADENOCARCINOMAS | ACQUIRED-RESISTANCE | EGFR | CELL LUNG-CANCER | ONCOLOGY | PHARMACOLOGY & PHARMACY | MUTATIONS | Neoplasms - metabolism | Receptor, Epidermal Growth Factor - genetics | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Quinazolinones - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacokinetics | Quinazolinones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - pathology | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Proto-Oncogene Proteins - genetics | Quinazolinones - blood | Protein Kinase Inhibitors - blood | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Asian Continental Ancestry Group | Tumor Burden - drug effects | Models, Biological | Antineoplastic Agents - blood | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasms - pathology | Studies | Clinical trials | Inhibitor drugs | Epidermal growth factor | Tumors | Index Medicus | Phase I Studies
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 2015, Volume 45, Issue 11, pp. 1016 - 1022
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, Issue suppl 7, pp. vii37 - vii37
Journal Article
Journal of Infection and Chemotherapy, ISSN 1341-321X, 2012, Volume 18, Issue 3, pp. 313 - 317
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2013, Volume 31, Issue 5, pp. 1265 - 1274
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 04/2019, Volume 14, Issue 4, pp. 672 - 682
Introduction: The study objective was to determine the incidence and characteristics of drug-induced interstitial lung disease (ILD) associated with an orally... 
Crizotinib | Interstitial lung disease | Tyrosine kinase inhibitor | Anaplastic lymphoma kinase-positive NSCLC | GEFITINIB | KINASE | CANCER | CHEMOTHERAPY | PROFILE | ONCOLOGY | RESPIRATORY SYSTEM | SURVEILLANCE | MUTATIONS | INHIBITOR | PREDICTIVE FACTORS | ERLOTINIB
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, Issue suppl 7, pp. vii74.2 - vii74
Journal Article
Japanese journal of clinical oncology, ISSN 0368-2811, 04/2019, Volume 49, Issue 7, pp. 676 - 686
Post-marketing surveillance (PMS) was performed in Japan to obtain information on the safety and efficacy of crizotinib. Target patients included almost all... 
anaplastic lymphoma kinase-positive non-small cell lung cancer | CELL LUNG-CANCER | post-marketing surveillance | crizotinib | ONCOLOGY | real-world data | Japanese | CHEMOTHERAPY
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 03/2019, Volume 49, Issue 4, pp. 354 - 360
Background In an interim analysis of a Phase II trial in Japanese patients with pancreatic neuroendocrine tumors (panNETs), sunitinib demonstrated antitumor... 
pancreatic neuroendocrine tumors | sunitinib | Japan | safety | efficacy | STREPTOZOCIN | ONCOLOGY | DOXORUBICIN | RENAL-CELL CARCINOMA | Index Medicus
Journal Article
Cancer Science, ISSN 1347-9032, 01/2010, Volume 101, Issue 1, pp. 188 - 195
Journal Article
Journal of Infection and Chemotherapy, ISSN 1341-321X, 2012, Volume 18, Issue 1, pp. 127 - 129
Journal Article
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 12/2018
The study objective was to determine the incidence and characteristics of drug-induced interstitial lung disease (ILD) associated with an orally available... 
Journal Article
Investigational New Drugs, ISSN 0167-6997, 4/2012, Volume 30, Issue 2, pp. 639 - 646
Journal Article
Cancer Research and Treatment, ISSN 1598-2998, 07/2018, Volume 50, Issue 3, pp. 691 - 700
Purpose Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and... 
Crizotinib | Carboplatin | Non-small cell lung carcinoma | Asia | Pemetrexed | Cisplatin | NSCLC | ONCOLOGY | Original
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.